Vistagen Therapeutics Inc VTGN.OQ VTGN.O is expected to show a fall in quarterly revenue when it reports results on February 13 for the period ending December 31 2024
The South San Francisco California-based company is expected to report a 56.2% decrease in revenue to $180 thousand from $411.4 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Vistagen Therapeutics Inc is for a loss of 51 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00, above its last closing price of $2.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.39 | -0.39 | -0.42 | Missed | -7.7 |
Jun. 30 2024 | -0.41 | -0.40 | -0.35 | Beat | 13.6 |
Mar. 31 2024 | -0.33 | -0.36 | -0.25 | Beat | 31 |
Dec. 31 2023 | -0.28 | -0.30 | -0.22 | Beat | 27.3 |
Sep. 30 2023 | -0.68 | -0.68 | -0.66 | Beat | 2.9 |
| |||||
Mar. 31 2023 | -1.50 | -1.75 | Missed | -16.7 | |
Dec. 31 2022 | -2.40 | -2.10 | -1.50 | Beat | 28.6 |
This summary was machine generated February 7 at 11:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。